ChemGenex Pharmaceuticals

ChemGenex Pharmaceuticals Ltd is an integrated biopharmaceutical development company dedicated to the discovery and development of oncology drugs. The company's candidate products include omacetaxine mepesuccinate, an investigational small molecule drug in Phase 2/3 clinical trials for the treatment of chronic myeloid leukemia, as well as in Phase 2 clinical trials for the treatment of acute myeloid leukemia and myelodysplastic syndrome; and Quinamed, which is in Phase 2 clinical trials for the treatment of hormone-refractory prostate cancer. Originally named AGT Biosciences Limited, the company changed its name to ChemGenex Pharmaceuticals Ltd in June 2004. It was founded in 1958 and is headquartered in Geelong, Australia.